Novartis In Line For Ofatumumab MS Approval In June
Will Rival Roche's Ocrevus
Executive Summary
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
You may also be interested in...
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Novartis MS Drug Mayzent Gets Europe OK
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.